Browse studies, page 423

Page 423 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer ClinicalTrials.gov · COMPLETED, 2013
• A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Erosive Reflux Disease ClinicalTrials.gov · COMPLETED, 2022
• Comparative Study of 10% Povidone-iodine Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers ClinicalTrials.gov · COMPLETED, 2008
• A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy ClinicalTrials.gov · COMPLETED, 2010
• Phase III: The Study of Acid Reflux in Children With Asthma ClinicalTrials.gov · COMPLETED, 2011
• A Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Efficacy of Fexuprazan for the Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids (FEAST) ClinicalTrials.gov · COMPLETED, 2025
• Anti-Helicobacter Pylori Therapy With Dexlansoprazole MR-Based Concomitant Quadruple Therapy- A Prospective Randomized Trial ClinicalTrials.gov · COMPLETED, 2019
• A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD) ClinicalTrials.gov · COMPLETED, 2018
• A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug ClinicalTrials.gov · COMPLETED, 2009
• Evaluation of Effects, Safety, Viral Load and Antibody Level of Functional Food Dietary Supplement Containing Grape Products in Controlled, Randomized Study Using SARSCoV-2 RT-PCR Positive Covid-19 Patients ClinicalTrials.gov · COMPLETED, 2021
• A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years ClinicalTrials.gov · COMPLETED, 2014
• A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients ClinicalTrials.gov · COMPLETED, 2004
• A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease ClinicalTrials.gov · COMPLETED, 2026
• A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn ClinicalTrials.gov · COMPLETED, 2007
• Effect of Proton Pump Inhibitor on Prevention of Tumor Bleeding in Patients Under Palliative Chemotherapy for Unresectable Gastric Cancer: a Randomized, Double Blind, and Placebo Controlled Multicenter Trial ClinicalTrials.gov · TERMINATED, 2017
• A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients With Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients With Healed Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2021
• A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy ClinicalTrials.gov · COMPLETED, 2003
• A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection ClinicalTrials.gov · COMPLETED, 2021
• A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2007
• A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2007
• A Randomized, Open-label, 2x2 Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics After Oral Administration of AD-212-A or AD-2121 in Healthy Adult Volunteers ClinicalTrials.gov · COMPLETED, 2024
• Can Detection of Fragments of Cleaved E-cadherin in Tissue and/or Blood be of Value for Identifying and Monitoring Patients With PPI-responsive Heartburn? ClinicalTrials.gov · COMPLETED, 2012
• A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD) ClinicalTrials.gov · COMPLETED, 2009
• A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD) ClinicalTrials.gov · COMPLETED, 2008
• Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial ClinicalTrials.gov · COMPLETED, 2016
• A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer ClinicalTrials.gov · COMPLETED, 2024
• Comparison of 7-day Proton Pump Inhibitor (PPI)-Clarithromycin Containing Triple Therapy and 10-day Bismuth Quadruple Therapy for Helicobacter Eradication as First-line Regimen: Randomized Controlled Trial ClinicalTrials.gov · COMPLETED, 2019
• A Phase 3, Double-blind, Randomized, Active-controlled Study to Evaluate the Safety and Efficacy of Tegoprazan as Maintenance Therapy in Patients With Healed Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2021
• A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD ClinicalTrials.gov · COMPLETED, 2007
• A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease ClinicalTrials.gov · COMPLETED, 2014
• A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to AG-1749 (15 mg Once-Daily) in a 24-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE) ClinicalTrials.gov · COMPLETED, 2013
• Prospective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic Esophagitis ClinicalTrials.gov · COMPLETED, 2013
• Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial in Taiwan ClinicalTrials.gov · COMPLETED, 2024
• A Phase 1 Double-blind, Dose-escalation, Placebo-controlled Tolerance Study in Healthy Chinese Adults After Single Intravenous Administration of Dexlansoprazole ClinicalTrials.gov · COMPLETED, 2017
• Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA. ClinicalTrials.gov · COMPLETED, 2014
• An Open-Label Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Subjects : TAK-390MR(OD)_107 ClinicalTrials.gov · COMPLETED, 2014
• Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux: A Double-Blind, Placebo Controlled, Randomized Clinical Trial ClinicalTrials.gov · COMPLETED, 2008
• An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors ClinicalTrials.gov · COMPLETED, 2020
• Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study ClinicalTrials.gov · COMPLETED, 2007
• A Prospective, Randomized, Double-Blind Protocol to Compare the Efficacy of Lansoprazole to Ranitidine in Healing Pre-Existing and/or Preventing the Development of Gastroduodenal Stress Ulceration and Postoperative Bleeding in Patients Undergoing Elective Coronary Artery Bypass Graft or Cardiac Valve Replacement Surgery ClinicalTrials.gov · TERMINATED, 2006
• A Pilot Study Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole 60 mg and Esomeprazole 40 mg for Gastroesophageal Reflux Disease Grade A and B ClinicalTrials.gov · COMPLETED, 2016
• A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer ClinicalTrials.gov · COMPLETED, 2023
• A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2012
• A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2006
• A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole ClinicalTrials.gov · COMPLETED, 2017
• A Relative Bioavailability Replicated Crossover Study of Lansoprazole 30 mg Delayed-Release Capsules Under Non-Fasting Conditions ClinicalTrials.gov · COMPLETED, 2003
• A Randomized, Open-label, Multiple Dose, Two-part Phase I Clinical Trial to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of DWP14012 After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects ClinicalTrials.gov · COMPLETED, 2019
• A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2003
• Comparison of Prilosec OTC® Versus Prevacid ® for Gastric Acid Suppression ClinicalTrials.gov · COMPLETED, 2009
• A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori ClinicalTrials.gov · COMPLETED, 2011
• Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity ClinicalTrials.gov · COMPLETED, 2015
• An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients ClinicalTrials.gov · COMPLETED, 2007
• A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Proof-of-Concept Trial to Assess Relief of Meal Induced Heartburn by a Combination of Lansoprazole 15 mg and Antacid Versus Lansoprazole 15 mg and Antacid (Calcium Carbonate and Magnesium Hydroxide) Alone ClinicalTrials.gov · COMPLETED
• The Effect of Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness ClinicalTrials.gov · TERMINATED, 2009
• A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial) ClinicalTrials.gov · COMPLETED, 2021
• A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer ClinicalTrials.gov · COMPLETED, 2018
• A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis ClinicalTrials.gov · TERMINATED, 2009
• Periodontal Tedavinin Helikobakter Pilori Eradikasyon ve Rekürrensine Katkısının İncelenmesi ClinicalTrials.gov · COMPLETED, 2012
• A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Phase III Clinical Study to Evaluate the Efficacy and Safety of X842 Capsules in Patients With Reflux Esophagitis ClinicalTrials.gov · COMPLETED, 2022
• Comparison of Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH by the Prior Administration of a Proton-pump Inhibitor: An Open-label 2-way Randomized Cross-over Study in Healthy Male and Female Subjects Age 40-65 ClinicalTrials.gov · COMPLETED
• The Pharmacokinetics and Pharmacodynamics of Two 30-mg Dexlansoprazole Delayed-Release Orally Disintegrating Tablets and One 60-mg Dexlansoprazole Delayed-Release Capsule: 1676 The American Journal of Gastroenterology, 2015
• A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers Journal of the American College of Cardiology, 2012
• Pharmacokinetics and bioequivalence of dexlansoprazole delayed release capsules in Beagle dogs Shenyang Yaoke Daxue xuebao, 2015
• Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease Alimentary Pharmacology and Therapeutics, 2013
• Method Development and Validation for Simultaneous Estimation of Dexlansoprazole and Meloxicam by Rp-Hplc Pharmaceutica Analytica Acta, 2015
• Dexlansoprazole-Induced Subacute Cutaneous Lupus Erythematosus (SCLE): 2166 The American Journal of Gastroenterology, 2016
• Determination of the Dexlansoprazole in Bulk and Spiked Human Plasma by Extraction Spectrophotometry International Letters of Chemistry, Physics and Astronomy, 2015
• Formulation and Evaluation of Dexlansoprazole Delayed Release Capsules Journal of Pharmacy & Pharmaceutics, 2016
• The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease Meditsinskiy sovet = Medical Council, 2018
• Design and In Vitro Characterization of Dexlansoprazole Controlled Release Tablets 2017
• Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis Expert Review of Gastroenterology & Hepatology, 2016
• Stereochemistrical Determination of Dexlansoprazole by Optical Rotation, ECD and 13 C-NMR Medicinal Chemistry, 2015
• Dexlansoprazole exposure and collagenous colitis: A case series Clinical Case Studies and Reports, 2018
• Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe Clinical and Experimental Gastroenterology, 2018
• Proton pump inhibitor dexlansoprazole in pure form and pharmaceutical formulations using alizarin derivatives International Journal of Research in Ayurveda and Pharmacy, 2018
• First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease World Journal of Gastroenterology, 2017
• Sensitive Analytical Liquid Chromatography-Tandem Mass Spectroscopy Method for the Estimation of Dexlansoprazole in Pharmaceutical Formulations Journal of Applied Pharmaceutical Sciences, 2018
• In-vitro evaluation of different available brands of dexlansoprazole MR capsules Journal of Applied Pharmacy, 2020
• Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial Drug Design, Development and Therapy, 2019
• Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study Asian Pacific Journal of Cancer Prevention, 2017
• Amikacin/dexlansoprazole Reactions weekly, 2021
• Formulation and evaluation of dexlansoprazole extended-release tablet GSC Biological and Pharmaceutical Sciences, 2021
• Cobalt ferrite magnetic nanoparticles as a highly efficient electrochemical platform for simultaneous determination of dexlansoprazole and granisetron hydrochloride Microchemical journal (Print), 2020
• Clinical Efficacy of Dexlansoprazole vs Esomeprazole in Gastro-Oesophageal Reflux Disease: A Randomized Clinical Trial Journal of Saidu Medical College, Swat, 2022
• Anti-ulcer and gastro protective effects of dexlansoprazole in experimentally induced gastric ulcer in rats Zagazig Veterinary Journal, 2023
• Outcome of Endoscopic Band Ligation in Cases with Gerd Refractory to Once Daily Medical Therapy of Dexlansoprazole International Journal of Science and Research (IJSR), 2023
• Comparative Analysis of Vonoprazan- and Dexlansoprazole-Based Therapies for Helicobacter pylori Eradication: A Single-Center Retrospective Observational Study Cureus, 2026
• Efficacy and safety of dexlansoprazole: a comprehensive review International Journal of Research in Medical Sciences, 2023
• Formulation and Evaluation of Pulsatile Drug Delivery System of Dexlansoprazole International Journal of Pharmaceutical Sciences and Nanotechnology, 2023
• Dexlansoprazole Versus Esomeprazole in Concomitant Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized, Open-Label, Non-Inferiority Trial SAS Journal of Medicine, 2026
• Development of controlled release formulations of dexlansoprazole to improve bioavailability International journal of medical laboratory research, 2024
• Development of Release Control Formulations of Dexlansoprazole and Pharmacokinetic Evaluation Journal of the Korea Academia-Industrial cooperation Society, 2024
• Formulating And Optimizing Gastroretentive Floating Dexlansoprazole for Enhanced Bioavailability In Vitro And In Vivo African Journal of Biomedical Research, 2024
• Formulation And Evaluation Of Floating Dexlansoprazole Systems Using Factorial Design African Journal of Biomedical Research, 2024
• Stability Indicating Validated Novel RP-HPLC Method for Dexlansoprazole and LC-MS/MS Study of Degradation Product Palestinian Medical and Pharmaceutical Journal, 2024
• Therapeutic Efficacy of Vonoprazan versus Dexlansoprazole in the Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Trial Afro-Egyptian Journal of Infectious and Endemic Diseases, 2025
• Method Validation for the Quantification of Dexlansoprazole dual-delayed release capsules by RP-HPLC Asian Journal of Pharmaceutical Analysis, 2025
• Major Allele Frequencies in CYP2C9 and CYP2C19 in Asian and European Populations: A Case Study to Disaggregate Data Among Large Racial Categories Journal of personalized medicine, 2025
• The oral‒gut axis in periodontal disease: a systematic review of the associated human evidence of its mechanisms and implications for patient care Journal of oral microbiology, 2026
• Optimizing proton-pump inhibitor therapy in paediatric eosinophilic esophagitis through CYP2C19 pharmacogenetic testing Journal of the Canadian Association of Gastroenterology, 2025